Fragmin

(dalteparin)

ApprovedSmall molecule

Pfizer

Fragmin is one of 444 small molecule programs targeting Fetal Growth Restriction. It is currently in Approved.

Indications

Total Trials

Active Trials

443

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Fetal Growth RestrictionActive, not recruiting

Venous ThromboembolismActive, not recruiting

Kidney CancerActive, not recruiting

Lung CancerActive, not recruiting

ThrombocytopeniaActive, not recruiting

Venous ThrombosisActive, not recruiting

Acute Coronary SyndromeActive, not recruiting

Nephrotic SyndromeActive, not recruiting

Deep Vein ThrombosisActive, not recruiting

Total Hip ArthroplastyActive, not recruiting

Fetal Growth RestrictionPreclinical

Active, not recruiting

Venous ThromboembolismPhase 2

Active, not recruiting

Kidney CancerPhase 1

Active, not recruiting

Lung CancerPhase 3

Active, not recruiting

ThrombocytopeniaApproved

Active, not recruiting

Venous ThrombosisPhase 2

Active, not recruiting

Acute Coronary SyndromeApproved

Active, not recruiting

Nephrotic SyndromePhase 1/Phase 2

Active, not recruiting

Deep Vein ThrombosisPhase 2

Active, not recruiting

Total Hip ArthroplastyApproved

Active, not recruiting

Showing 10 of 17 indications

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Fragmin

Pfizer

Approved

1 2

Bnt162b2

BioNTech

Preclinical

29 3

Biaxin

AbbVie

Preclinical

2 4

Singulair

AstraZeneca

Preclinical

1 5

Aimovig

Amgen

Preclinical

1 6

Nexavar

Bayer

Preclinical

1 7

Calciferol

Alnylam Pharmaceuticals

Activella

Rayaldee

1 10

Aquasol E

NNational Eye Institute (NEI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Post-ApprovalRecruiting

Thrombocytopenia

NCT05255003

Phase 3Active, not recruiting

Genitourinary Cancer

NCT05171075

Q4 2027

Phase 3Recruiting

Venous Thromboembolism

NCT03559114

Q3 2028

Phase 3Recruiting

Thrombosis

NCT06370273

Q2 2031

Phase 3Not yet recruiting

Critical Illness

NCT06628778

Clinical

Trials by Indication[1]

Venous Thromboembolism9 trials

Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients

Completed·OOntario Clinical Oncology Group (OCOG)·Phase 3·NCT00135876·512 enrolled

WAVe Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous Thromboembolism

Terminated·OOttawa Hospital Research Institute·Phase 2·NCT03297359·92 enrolled

A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism

Unknown status·—·Phase 2·NCT03139487·176 enrolled

Show 6 more trials

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

Completed·—·Phase 3·NCT02585713·300 enrolled

Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients

Completed·MM.D. Anderson Cancer Center·Phase 4·NCT00966277·87 enrolled

Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer

Completed·FFadoi Foundation, Italy·Phase 3·NCT03045406·1,170 enrolled

PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury (PROTEST)

Recruiting·SSunnybrook Health Sciences Centre·Phase 3·NCT03559114·1,100 enrolled

Cancer Venous Thromboembolism (VTE)

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT02073682·1,046 enrolled

Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients

Terminated· Pfizer logo

Pfizer·Phase 4·NCT00445328·84 enrolled

Pancreatic Cancer2 trials

Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Terminated·GGary Morrow·Phase 3·NCT00031837·400 enrolled

Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Completed·HHull University Teaching Hospitals NHS Trust·Phase 2·NCT00462852·120 enrolled

Treatment2 trials

Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo

Completed·—·Phase 2·NCT01419977·34 enrolled

Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer

Completed· Pfizer logo

Pfizer·Phase 4·NCT00942968·338 enrolled

Lung Cancer2 trials

Dalteparin in Preventing Blood Clots in Patients With Lung Cancer

Unknown status·VVelindre NHS Trust·Phase 3·NCT00519805·2,200 enrolled

Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer

Completed·TThomas Decker Christensen·Phase 4·NCT01741506·116 enrolled

Acute Coronary Syndrome2 trials

Dalteparin Versus Unfractionated Heparin In Patients With Acute Coronary Syndrome

Terminated· Pfizer logo

Pfizer·Phase 4·NCT00435487·173 enrolled

Effectiveness And Safety Of Dalteparin In Patients With Acute Coronary Syndromes Without ST Elevations In Clinical Practice

Completed· Pfizer logo

Pfizer··NCT00922766·618 enrolled

28 more indications

Glioblastoma Multiforme1 trial

Dalteparin and Radiation Therapy in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00028678·45 enrolled

Multiple Myeloma1 trial

Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma

Terminated·UUniversity of Southern California·Phase 2·NCT01518465·13 enrolled

Effectiveness1 trial

PERIOP 2 - A Safety and Effectiveness of LMWH vs Placebo Bridging Therapy for Patients on Long Term Warfarin Requiring Temporary Interruption of Warfarin.

Unknown status·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 3·NCT00432796·1,473 enrolled

Bariatric Surgery1 trial

Venous Thromboprophylaxis in Bariatric Surgery

Completed·GGroupe Hospitalier Pitie-Salpetriere··NCT03218514·118 enrolled

Dialysis Patients1 trial

A New Anticoagulation Method Using Dalteparin in Quotidian and Nocturnal Home Hemodialysis Patients

Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 4·NCT02607111·15 enrolled

Prostate Cancer1 trial

Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00003674·141 enrolled

Cancer1 trial

Dalteparin in Preventing DVT in Participants With Cancer

Completed·MM.D. Anderson Cancer Center·N/A·NCT00525057·65 enrolled

Fetal Growth Restriction1 trial

LMWH to Prevent Preeclampsia and Fetal Growth Restriction

Terminated·UUniversity of Florence··NCT00260520

Kidney Cancer1 trial

Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery

Completed·RRoswell Park Cancer Institute·Phase 1·NCT01061411·16 enrolled

Critical Illness1 trial

Collaborative Risk-stratified Investigation in Teen Inpatients With Critical Illness: Anticoagulation With LMWH in Kids for ThromboProphylaxis (CRITICAL-Kids-TP)

Not yet recruiting·JJohns Hopkins All Children's Hospital·Phase 3·NCT06628778·802 enrolled

Anticoagulation1 trial

Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)

Completed·—·Phase 3·NCT00786474·1,884 enrolled

Low Molecular Weight Heparin1 trial

Efficacy of Low Molecular Weight Heparin in Superficial Vein Thrombosis

Completed·UUniversity Medical Centre Ljubljana·Phase 4·NCT01245998·68 enrolled

MPR1 trial

Alterations of Blood Clotting With the Use of Sequential Compression Devices on the Lower Limbs

Terminated·UUniversity of Parma·N/A·NCT00726570·40 enrolled

Pediatric Cancer1 trial

Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients

Completed· Pfizer logo

Pfizer·Phase 2·NCT00952380·38 enrolled

Direct Oral Anticoagulants (DOACs)1 trial

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

Completed·AAlliance Foundation Trials, LLC.·N/A·NCT02744092·811 enrolled

Thrombocytopenia1 trial

STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis

Recruiting·TTzu-Fei Wang·Phase 4·NCT05255003·50 enrolled

Ovarian Cancer1 trial

Fragmin in Ovarian Cancer: Utility on Survival (FOCUS)

Completed·OOntario Clinical Oncology Group (OCOG)·Phase 2·NCT00239980·77 enrolled

Septic Shock1 trial

Heparin Anticoagulation to Improve Outcomes in Septic Shock: The HALO Pilot

Completed·UUniversity of Manitoba·Phase 2·NCT01648036·76 enrolled

Prophylaxis1 trial

A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients

Terminated·UUniversity of Rochester·Phase 3·NCT00876915·218 enrolled

Venous thrombosis1 trial

Outpatient Treatment Of Deep Venous Thrombosis Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00041782·26 enrolled

COVID-191 trial

Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial

Active, not recruiting·UUniversity of Melbourne·Phase 3·NCT04483960·2,200 enrolled

Total Hip Arthroplasty1 trial

Preoperative Versus Postoperative Start With Thromboprophylaxis in THA (Total Hip Arthroplasty)

Completed·VVestre Viken Hospital Trust·Phase 4·NCT01714297·80 enrolled

Critically Ill Patients1 trial

Thromboprophylaxis in Critically Ill Patients

Terminated·MMedical University of Vienna·Phase 4·NCT00437697·90 enrolled

Nephrotic Syndrome1 trial

Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome

Completed·UUniversity of Aarhus·Phase 1/2·NCT04850378·57 enrolled

Deep Vein Thrombosis1 trial

The Catheter Study: Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis

Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2·NCT00216866·70 enrolled

Genitourinary Cancer1 trial

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

Active, not recruiting·AAnthos Therapeutics, Inc.·Phase 3·NCT05171075·417 enrolled

Anticoagulant1 trial

Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery

Completed· GSK logo

GSK··NCT01444612·4,068 enrolled

Thrombosis1 trial

Thromboprophylaxis in Lower Limb Immobilisation (TiLLI): a Multicentre Study Comprising Two Linked Open Label Phase III Randomised Controlled Trials Evaluating the Effectiveness and Cost Effectiveness of Different Methods of Pharmacological Prophylaxis for Patients With Temporary Lower Limb Immobilisation.

Recruiting·QQueen Mary University of London·Phase 3·NCT06370273·10,044 enrolled

Regulatory

FDA Approval Timeline[4]

Apr 4, 2002

FRAGMIN

NDA NDA020287

Sources

References

[1]
ClinicalTrials.gov — 45 trial records for dalteparin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — dalteparin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for dalteparin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020287). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Pfizer

Fragmin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Q3 2028

Q2 2031

Trials by Indication[1]

Venous Thromboembolism9 trials

Pancreatic Cancer2 trials

Treatment2 trials

Lung Cancer2 trials

Acute Coronary Syndrome2 trials

Glioblastoma Multiforme1 trial

Multiple Myeloma1 trial

Effectiveness1 trial

Bariatric Surgery1 trial

Dialysis Patients1 trial

Prostate Cancer1 trial

Cancer1 trial

Fetal Growth Restriction1 trial

Kidney Cancer1 trial

Critical Illness1 trial

Anticoagulation1 trial

Low Molecular Weight Heparin1 trial

MPR1 trial

Pediatric Cancer1 trial

Direct Oral Anticoagulants (DOACs)1 trial

Thrombocytopenia1 trial

Ovarian Cancer1 trial

Septic Shock1 trial

Prophylaxis1 trial

Venous thrombosis1 trial

COVID-191 trial

Total Hip Arthroplasty1 trial

Critically Ill Patients1 trial

Nephrotic Syndrome1 trial

Deep Vein Thrombosis1 trial

Genitourinary Cancer1 trial

Anticoagulant1 trial

Thrombosis1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News